Asset Details
Do you wish to reserve the book?
Measles, mumps, and rubella virus vaccine (M–M–R™II): A review of 32 years of clinical and postmarketing experience
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Measles, mumps, and rubella virus vaccine (M–M–R™II): A review of 32 years of clinical and postmarketing experience
Do you wish to request the book?
Measles, mumps, and rubella virus vaccine (M–M–R™II): A review of 32 years of clinical and postmarketing experience
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Measles, mumps, and rubella virus vaccine (M–M–R™II): A review of 32 years of clinical and postmarketing experience
2012
Overview
► The 32-year safety profile of M–M–R™II is described using data from postmarketing surveillance. ► Of ∼575 million doses distributed, 17,536 AEs were voluntarily reported (30.5 AEs/1×106 doses). ► This review provides evidence that the vaccine is safe and well-tolerated.
M–M–R™II (measles, mumps, and rubella virus vaccine live; Merck, Sharp, & Dohme Corp.) is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals ≥12 months of age. Before the vaccine era, these viruses infected most exposed individuals, with subsequent morbidity and mortality. One of the greatest achievements of public health has been to eliminate these 3 diseases in large geographic areas.
The safety profile of M–M–R™II is described using data from routine global postmarketing surveillance. Postmarketing surveillance has limitations (including incomplete reporting of case data), but allows collection of real-world information on large numbers of individuals, who may have concurrent medical problems excluding them from clinical trials. It can also identify rare adverse experiences (AEs).
Over its 32-year history, ∼575 million doses of M–M–R™II have been distributed worldwide, with 17,536 AEs voluntarily reported for an overall rate of 30.5 AEs/1,000,000 doses distributed. This review provides evidence that the vaccine is safe and well-tolerated.
Publisher
Elsevier Ltd
Subject
/ Drug-Related Side Effects and Adverse Reactions - epidemiology
/ Humans
/ Measles
/ Measles - prevention & control
/ Measles-Mumps-Rubella Vaccine - administration & dosage
/ Measles-Mumps-Rubella Vaccine - adverse effects
/ Measles-Mumps-Rubella Vaccine - immunology
/ Mumps
/ Mumps - prevention & control
/ Product Surveillance, Postmarketing
/ Reviews
/ Rubella
/ Rubella - prevention & control
/ Safety
/ Vaccine
/ Vaccines
/ Viruses
